CA-LINKSYS
13.9.2023 22:48:28 CEST | Business Wire | Press release
Linksys®, an iconic Home and Small Office connectivity company, announces in a statement of direction its new Cognitive Experience technology. Cognitive Experience brings a whole new level of intelligence to networking with cutting-edge technological features specially designed to enhance and improve the user experience.
In the technology space, the word “cognitive” refers to “thinking technologies” that can deterministically – either by user selection or automation – solve problems. Developed based on user input and feedback, Cognitive Experience focuses on saving time and effort by automating the process for reporting technical issues to customer support agents.
“Currently 50% of our Support calls are dead air, nobody talking, as our Guardians review the logs and network information while the customer is on the phone,” said Lucas Peterson, Head of Product Support at Linksys. “With Linksys Cognitive Experience, we get all the information we need sent upfront through automation so that our Guardians can review and diagnose before they call the customer. This coupled with our ability to temporarily co-administer the network — with the customer’s permission, of course — will enable us to solve problems in lightning-fast time.”
Cognitive Experience allows a Linksys customer service agent to analyze your technical issue remotely, so that when they contact the user, they have all the information necessary to address the problem. Customer service agents can then administer tech support remotely through your network. You’re able to grant or rescind access to the network at any time. This allows customer service agents to effectively tackle any issues in lightning-fast time.
In Phase 1 of its implementation, Cognitive Experience features will focus on the following:
- If you experience a problem with your WiFi network, Cognitive Experience is able to run a test on your network
- Open a trouble-ticket from the Linksys App and get a call from Linksys customer service agents
- An agent will review the report and can easily access your network, with your permission, to address the problem
- Cognitive Experience will run a health check on your network to locate any additional potential issues
Phase 1 of Linksys Cognitive Experience is set to be completed by the end of this calendar year. Cognitive Experience will make its debut with products in the Linksys Designer Series through the end of the year. Starting in 2024, Cognitive Experience will be available in other Linksys products.
Phase 2 of Linksys Cognitive Experience is currently under development and includes new “intelligent notifications” that humanize or personalize the insights derived from your network, delivered in a meaningful way.
Examples of intelligent notifications include:
- When a network’s WAN goes down, we verify the Home Network is operating and then send a WAN Down notification
- When a network’s WAN comes back up, we verify it and retest the Home Network and send WAN Up and Home Network Up notifications
- Users can select certain devices to be notified when they leave and rejoin the network
Designer Series offerings that include Cognitive Experience are:
- Velop Pro 6E – currently available in the US at Amazon, Best Buy and Linksys.com
- Velop Pro 7 – expected in September/October, now available for pre order at Amazon and Best Buy
- Velop Micro Router 6 – expected in October/November
- Velop Micro Mesh 6 – expected in October/November
About Linksys
At Linksys, we engineer simplicity so that you never experience complexity. Linksys is an iconic brand celebrating its 35th year of innovation in Home and Small Office connectivity. With many industry firsts to its credit, Linksys delivers simple, fast, reliable, and affordable products for the Home and Small Office where there is “no IT.”
© 2023 Linksys Holdings, Inc. and/or its affiliates. All rights reserved.
Linksys and many product names and logos are trademarks of Linksys Holdings Inc. and/or its affiliates. Third-party trademarks mentioned are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913706425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
